Association of Serum Interleukin 6 and C-Reactive Protein in Childhood With Depression and Psychosis in Young Adult Life: A Population-Based Longitudinal Study | Depressive Disorders | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
1.
Murray  CJ, Lopez  AD.  Measuring the global burden of disease.  N Engl J Med. 2013;369(5):448-457.PubMedGoogle ScholarCrossref
2.
Kessler  RC, Berglund  P, Demler  O,  et al; National Comorbidity Survey Replication.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).  JAMA. 2003;289(23):3095-3105.PubMedGoogle ScholarCrossref
3.
Kessler  RC, Berglund  P, Demler  O, Jin  R, Merikangas  KR, Walters  EE.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.  Arch Gen Psychiatry. 2005;62(6):593-602.PubMedGoogle ScholarCrossref
4.
Kendler  KS, Gallagher  TJ, Abelson  JM, Kessler  RC.  Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: the National Comorbidity Survey.  Arch Gen Psychiatry. 1996;53(11):1022-1031.PubMedGoogle ScholarCrossref
5.
World Health Organization.  The Global Burden of Disease: 2004 Update. Geneva, Switzerland: World Health Organization; 2008.
6.
Saha  S, Chant  D, McGrath  J.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?  Arch Gen Psychiatry. 2007;64(10):1123-1131.PubMedGoogle ScholarCrossref
7.
Danesh  J, Kaptoge  S, Mann  AG,  et al.  Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review.  PLoS Med. 2008;5(4):e78. doi:10.1371/journal.pmed.0050078.PubMedGoogle ScholarCrossref
8.
Danesh  J, Wheeler  JG, Hirschfield  GM,  et al.  C-Reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.  N Engl J Med. 2004;350(14):1387-1397.PubMedGoogle ScholarCrossref
9.
Kaptoge  S, Di Angelantonio  E, Pennells  L,  et al; Emerging Risk Factors Collaboration.  C-reactive protein, fibrinogen, and cardiovascular disease prediction.  N Engl J Med. 2012;367(14):1310-1320.PubMedGoogle ScholarCrossref
10.
Pradhan  AD, Manson  JE, Rifai  N, Buring  JE, Ridker  PM.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.  JAMA. 2001;286(3):327-334.PubMedGoogle ScholarCrossref
11.
Pradhan  AD, Manson  JE, Rossouw  JE,  et al.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study.  JAMA. 2002;288(8):980-987.PubMedGoogle ScholarCrossref
12.
Anda  R, Williamson  D, Jones  D,  et al.  Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults.  Epidemiology. 1993;4(4):285-294.PubMedGoogle ScholarCrossref
13.
Bushe  C, Holt  R.  Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia.  Br J Psychiatry Suppl. 2004;47:S67-S71.PubMedGoogle ScholarCrossref
14.
Belmaker  RH, Agam  G.  Major depressive disorder.  N Engl J Med. 2008;358(1):55-68.PubMedGoogle ScholarCrossref
15.
Carlton  PL, Manowitz  P.  Dopamine and schizophrenia: an analysis of the theory.  Neurosci Biobehav Rev. 1984;8(1):137-151.PubMedGoogle ScholarCrossref
16.
Dantzer  R, O’Connor  JC, Freund  GG, Johnson  RW, Kelley  KW.  From inflammation to sickness and depression: when the immune system subjugates the brain.  Nat Rev Neurosci. 2008;9(1):46-56.PubMedGoogle ScholarCrossref
17.
Miller  BJ, Buckley  P, Seabolt  W, Mellor  A, Kirkpatrick  B.  Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.  Biol Psychiatry. 2011;70(7):663-671.PubMedGoogle ScholarCrossref
18.
Miller  AH, Maletic  V, Raison  CL.  Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression.  Biol Psychiatry. 2009;65(9):732-741.PubMedGoogle ScholarCrossref
19.
Reichenberg  A, Yirmiya  R, Schuld  A,  et al.  Cytokine-associated emotional and cognitive disturbances in humans.  Arch Gen Psychiatry. 2001;58(5):445-452.PubMedGoogle ScholarCrossref
20.
Khandaker  GM, Zimbron  J, Lewis  G, Jones  PB.  Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies.  Psychol Med. 2013;43(2):239-257.PubMedGoogle ScholarCrossref
21.
Benros  ME, Nielsen  PR, Nordentoft  M, Eaton  WW, Dalton  SO, Mortensen  PB.  Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study.  Am J Psychiatry. 2011;168(12):1303-1310.PubMedGoogle ScholarCrossref
22.
Khandaker  GM, Zimbron  J, Dalman  C, Lewis  G, Jones  PB.  Childhood infection and adult schizophrenia: a meta-analysis of population-based studies.  Schizophr Res. 2012;139(1-3):161-168.PubMedGoogle ScholarCrossref
23.
Benros  ME, Waltoft  BL, Nordentoft  M,  et al.  Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study.  JAMA Psychiatry. 2013;70(8):812-820.PubMedGoogle ScholarCrossref
24.
Howren  MB, Lamkin  DM, Suls  J.  Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.  Psychosom Med. 2009;71(2):171-186.PubMedGoogle ScholarCrossref
25.
Gardner  RM, Dalman  C, Wicks  S, Lee  BK, Karlsson  H.  Neonatal levels of acute phase proteins and later risk of non-affective psychosis.  Transl Psychiatry. 2013;3:e228. doi:10.1038/tp.2013.5.PubMedGoogle ScholarCrossref
26.
Wium-Andersen  MK, Ørsted  DD, Nielsen  SF, Nordestgaard  BG.  Elevated C-reactive protein levels, psychological distress, and depression in 73 131 individuals.  JAMA Psychiatry. 2013;70(2):176-184.PubMedGoogle ScholarCrossref
27.
Gimeno  D, Kivimäki  M, Brunner  EJ,  et al.  Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study.  Psychol Med. 2009;39(3):413-423.PubMedGoogle ScholarCrossref
28.
Matthews  KA, Schott  LL, Bromberger  JT, Cyranowski  JM, Everson-Rose  SA, Sowers  M.  Are there bi-directional associations between depressive symptoms and C-reactive protein in mid-life women?  Brain Behav Immun. 2010;24(1):96-101.PubMedGoogle ScholarCrossref
29.
Lewis  G, Pelosi  AJ, Araya  R, Dunn  G.  Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers.  Psychol Med. 1992;22(2):465-486.PubMedGoogle ScholarCrossref
30.
Angold  A, Costello  EJ, Messer  SC.  Development of a short questionnaire for use in epidemiological studies of depression in children and adolescents.  Int J Methods Psychiatr Res. 1995;5:237-249.Google Scholar
31.
Zammit  S, Kounali  D, Cannon  M,  et al.  Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study.  Am J Psychiatry. 2013;170(7):742-750.PubMedGoogle ScholarCrossref
32.
World Health Organization.  SCAN: Schedules for Clinical Assessment in Neuropsychiatry, Version 2.0. Geneva, Switzerland: Psychiatric Publishers International/American Psychiatric Press Inc; 1994.
33.
Goodman  R.  The Strengths and Difficulties Questionnaire: a research note.  J Child Psychol Psychiatry. 1997;38(5):581-586.PubMedGoogle ScholarCrossref
34.
Rutter  M, Kim-Cohen  J, Maughan  B.  Continuities and discontinuities in psychopathology between childhood and adult life.  J Child Psychol Psychiatry. 2006;47(3-4):276-295.PubMedGoogle ScholarCrossref
35.
White  IR, Royston  P, Wood  AM.  Multiple imputation using chained equations: issues and guidance for practice.  Stat Med. 2011;30(4):377-399.PubMedGoogle ScholarCrossref
36.
Knudsen  LS, Christensen  IJ, Lottenburger  T,  et al.  Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis.  Biomarkers. 2008;13(1):59-78.PubMedGoogle ScholarCrossref
37.
de Jager  W, Bourcier  K, Rijkers  GT, Prakken  BJ, Seyfert-Margolis  V.  Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays.  BMC Immunol. 2009;10:52. doi:10.1186/1471-2172-10-52.PubMedGoogle ScholarCrossref
38.
Janeway  CA, Travers  P, Walport  M, Shlomchik  MJ.  Immunobiology: The Immune System in Health and Disease.5th ed. New York, NY: Garland Science; 2001.
39.
Müller  N, Schwarz  MJ, Dehning  S,  et al.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.  Mol Psychiatry. 2006;11(7):680-684.PubMedGoogle ScholarCrossref
40.
Müller  N, Riedel  M, Scheppach  C,  et al.  Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.  Am J Psychiatry. 2002;159(6):1029-1034.PubMedGoogle ScholarCrossref
41.
Mukherjee  D, Nissen  SE, Topol  EJ.  Risk of cardiovascular events associated with selective COX-2 inhibitors.  JAMA. 2001;286(8):954-959.PubMedGoogle ScholarCrossref
42.
Chaudhry  IB, Hallak  J, Husain  N,  et al.  Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment.  J Psychopharmacol. 2012;26(9):1185-1193.PubMedGoogle ScholarCrossref
43.
American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders.ed 4. Washington, DC: American Psychiatric Association; 1994.
44.
Green  EK, Grozeva  D, Jones  I,  et al; Wellcome Trust Case Control Consortium.  The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia.  Mol Psychiatry. 2010;15(10):1016-1022.PubMedGoogle ScholarCrossref
45.
Barker  DJP, Robinson RJ.  Fetal and Infant Origins of Adult Disease. 1st ed. London, England: BMJ Books; 1992.
46.
Tzoulaki  I, Jarvelin  MR, Hartikainen  AL,  et al.  Size at birth, weight gain over the life course, and low-grade inflammation in young adulthood: northern Finland 1966 Birth Cohort study.  Eur Heart J. 2008;29(8):1049-1056.PubMedGoogle ScholarCrossref
47.
Abel  KM, Wicks  S, Susser  ES,  et al.  Birth weight, schizophrenia, and adult mental disorder: is risk confined to the smallest babies?  Arch Gen Psychiatry. 2010;67(9):923-930.PubMedGoogle ScholarCrossref
Original Investigation
October 2014

Association of Serum Interleukin 6 and C-Reactive Protein in Childhood With Depression and Psychosis in Young Adult Life: A Population-Based Longitudinal Study

Author Affiliations
  • 1Department of Psychiatry, University of Cambridge, Cambridge, England
  • 2National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, England
  • 3Collaboration for Leadership in Applied Health Research and Care, East of England, Cambridge, England
  • 4Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge, England
  • 5Centre for Mental Health, Addiction and Suicide Research, School of Social and Community Medicine, University of Bristol, Bristol, England
  • 6Institute of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales
  • 7Division of Psychiatry, University College London, London, England
JAMA Psychiatry. 2014;71(10):1121-1128. doi:10.1001/jamapsychiatry.2014.1332
Abstract

Importance  Longitudinal studies have linked the systemic inflammatory markers interleukin 6 (IL-6) and C-reactive protein (CRP) with the risk of developing heart disease and diabetes mellitus, which are common comorbidities for depression and psychosis. Recent meta-analyses of cross-sectional studies have reported increased serum levels of these inflammatory markers in depression, first-episode psychosis, and acute psychotic relapse; however, the direction of the association has been unclear.

Objective  To test the hypothesis that higher serum levels of IL-6 and CRP in childhood would increase future risks for depression and psychosis.

Design, Setting, and Participants  The Avon Longitudinal Study of Parents and Children (ALSPAC)is a prospective general population birth cohort study based in Avon County, England. We have studied a subsample of approximately 4500 individuals from the cohort with data on childhood IL-6 and CRP levels and later psychiatric assessments.

Measurement of Exposure  Levels of IL-6 and CRP were measured in nonfasting blood samples obtained in participants at age 9 years.

Main Outcomes and Measures  Participants were assessed at age 18 years. Depression was measured using the Clinical Interview Schedule–Revised (CIS-R) and Mood and Feelings Questionnaire (MFQ), thus allowing internal replication; psychotic experiences (PEs) and psychotic disorder were measured by a semistructured interview.

Results  After adjusting for sex, age, body mass index, ethnicity, social class, past psychological and behavioral problems, and maternal postpartum depression, participants in the top third of IL-6 values compared with the bottom third at age 9 years were more likely to be depressed (CIS-R) at age 18 years (adjusted odds ratio [OR], 1.55; 95% CI, 1.13-2.14). Results using the MFQ were similar. Risks of PEs and of psychotic disorder at age 18 years were also increased with higher IL-6 levels at baseline (adjusted OR, 1.81; 95% CI, 1.01-3.28; and adjusted OR, 2.40; 95% CI, 0.88-6.22, respectively). Higher IL-6 levels in childhood were associated with subsequent risks of depression and PEs in a dose-dependent manner.

Conclusions and Relevance  Higher levels of the systemic inflammatory marker IL-6 in childhood are associated with an increased risk of developing depression and psychosis in young adulthood. Inflammatory pathways may provide important new intervention and prevention targets for these disorders. Inflammation might explain the high comorbidity between heart disease, diabetes mellitus, depression, and schizophrenia.

×